GSK

Shaping a Healthier Tomorrow

HALF YEAR REPORT 2026

Group Ownership Structure

GSK Plc (100%)

GlaxoSmithKline Holdings Limited (100%)

GSK Finance Plc (100%)

Setfirst Limited (100%)

GSK International Holding Finance B.V (82.59%)

GlaxoSmithKline Pakistan Limited

Corporate Information

As at June 30, 2026

Board of Directors

Mr. Dmytro Oliinyk*
Chairperson

Ms. Erum Shakir Rahim
Chief Executive Officer

Mr. Hasham Ali Baber**
Chief Financial Officer

Mr. Asad Said Jafar***
Independent Director

Mr. Muneer Kamal
Independent Director

Mr. Naved Masoom Ali****
Executive Director

Ms. Ana Paula De Freitas Passos*****
Non-Executive Director

Audit Committee

Mr. Muneer Kamal
Chairman

Mr. Dmytro Oliinyk*
Member

Mr. Hasham Ali Baber**
Member

Mr. Asad Said Jafar***
Member

Mr. Kashif Rafiq
Secretary

Human Resource & Remuneration Committee

Mr. Asad Said Jafar***
Chairperson

Mr. Muneer Kamal
Member

Mr. Dmytro Oliinyk*
Member

Ms. Erum Shakir Rahim
Member

Ms. Sabiqa Kiyani
Secretary

Disclosure Committee

Ms. Erum Shakir Rahim
Chairperson

Mr. Dmytro Oliinyk*
Member

Mr. Naved Masoom Ali****
Member

Ms. Hina Mir
Member

Mr. Hasham Ali Baber**
Secretary

Sustainability Committee******

Ms. Erum Shakir Rahim
Member

Mr. Asad Said Jafar***
Member

Mr. Dmytro Oliinyk*
Member

Mr. Hasham Ali Baber**
Member

Mr. Muhammad Kashif Ayub
Secretary

Management Committee

Ms. Erum Shakir Rahim
Chief Executive Officer

Mr. Hasham Ali Baber**
Chief Financial Officer

Ms. Hina Mir
Legal Director

Dr. Tariq Farooq
Director Business Unit 1 & 2

Mr. Naved Masoom Ali
Director Business Unit 3 & CTC

Mr. Rafay Ahmed
Director Commercial Operations

Dr. Gohar Nayab Khan
Head of Regulatory Affairs

Dr. Yousuf Hasan Khan
Director Medical

Syed Nabigh Raza Alam
Tech Head

Ms. Sabiqa Kiyani
HR Country Head

Ms. Andleeb Uroos Ahmed
Director Communications & Government Affairs

Mr. Khurshand Iqbal
Site Director - F/268

Mr. Muhammad Kashif Ayub
Site Director - West Wharf

Mr. Masood Khan
Site Director - Korangi

Company Secretary

Ms. Hina Mir

Chief Financial Officer

Mr. Hasham Ali Baber**

Chief Internal Auditor

Mr. Kashif Rafiq

Bankers

Standard Chartered Bank (Pakistan) Ltd
Citibank NA Pakistan
Deutsche Bank A.G. Pakistan Operations
Habib Bank Limited
Meezan Bank Limited

Auditors

Yousuf Adil Chartered Accountants

Legal Advisors

Hashmi & Hashmi
Faisal, Mahmood Ghani and Co
Legal Consultancy Inc.

Registered Office

35 - Dockyard Road, West Wharf,
Karachi - 74000.
Tel: 92-21-111-475-725
(111-GSK-PAK)
Website: www.pk.gsk.com

Share Registrar

CDC Share Registrar Services Limited
CDC House, 99 – B, Block 'B',
S.M.C.H.S., Main Shahra-e-Faisal
Karachi – 74400, Pakistan
Tel: Customer Support Services
(Toll Free) 0800-CDCPL (23275)
Fax: (92-21) 34326053
Email: info@cdcsrsl.com
Website: www.cdcsrsl.com

* Mr. Dmytro Oliinyk has appointed as Chairperson and Non-Executive Director on 6th April, 2026 and subsequently, re-elected on 25th May 2026.
**Mr. Hasham Ali Babar has resigned from the position of Chief Financial Officer on 30th June, 2026 and has been appointed as Non Executive Director with effect from 30th July, 2026
The position of Disclosure committee's secretary is vacant.
***Mr. Asad Said Jafar has been appointed as the Independent Director, with effect from 25th, May 2026
****Mr. Naved Masoom Ali has been appointed as the Executive Director, with effect from 25th, May 2026
*****Ms. Ana Paula De Freitas Passos has resigned from the position of Non-Executive Director with effect from 31st, May 2026.
******The position of chairperson for sustainability commitee is vacant.
*******Ms Maheen Rahman and Mr. Memood Mandviwala has left the board from the position of Independent Director and Non Executive Director respectvely w.e.f 24th May 2026.
********Mr. Umair Majeed has been appointed as Interim Chief Financial Officer on July 30, 2026

Directors' Report to the Shareholders

The Directors of GlaxoSmithKline Pakistan Limited (the "Company") are pleased to present the un-audited financial information of your Company for the six months period ended June 30, 2026. This financial information is submitted in accordance with Section 227 of the Companies Act, 2017.

Business environment and challenges:
Pakistan's economy continued to demonstrate signs of stabilisation and recovery during first half of FY 2026, with GDP growth estimated at approximately 3.7%. This was supported by continued engagement with the IMF, fiscal consolidation efforts, and prudent monetary and exchange rate management. Strong remittance inflows, stable foreign exchange reserves, and a relatively stable Pakistani Rupee supported economic activity and external sector resilience. Despite these encouraging developments, economy continues to face risks including structural challenges, global energy price volatility, geopolitical uncertainties, supply chain disruptions, high inflation and domestic cost pressures, which continue to weigh on the overall business environment.

The Federal Budget FY2026–27 reinforces the Government's commitment to macroeconomic stability and fiscal consolidation through higher tax collection, broader economic documentation and strengthened compliance measures. Tax relief for the salaried class, reduction in super tax for corporates and some relief on duties applicable to Active Pharmaceutical Ingredients (APIs) are positive policy measures. Going forward, sustained structural reforms and continued improvements in the business environment will be essential to promoting investment, enhancing competitiveness and supporting long-term economic growth.

The Company remains dedicated to addressing the healthcare needs of the country by ensuring patients have access to high-quality medicines while striving to improve profitability and shareholder returns. While the Company continues to engage with the relevant authorities on pending pricing hardship cases for certain essential medicines and pricing threshold matters relating to non-essential products, it remains focused on sustainability measures, operational efficiency, and cost optimization initiatives to support long-term growth and value creation.

Review of Operating Results:
For the period ended June 30, 2026, the Company achieved net sales of Rs. 31.5 billion. Net sales included sales to Haleon Pakistan Limited (Haleon) of Rs. 0.49 billion, compared to Rs. 0.57 billion in the same period last year. Excluding these specific sales, the underlying sales growth is 4.4%. This growth is mainly driven by price increases and tender business.

The gross margin of the Company for the period was 37.8% showing an increase of 2.5% from the last period. This higher gross profit percentage is due to price increases through deregulation of non-essential products and various profitability and sustainability measures.

During the quarter, the Company continued to prudently invest behind key business drivers to deliver competitive growth and higher return on investment.

Earnings per share for this period increased from Rs. 13.17 to Rs. 14.38.

Future Outlook
Geopolitical tensions and regional conflicts continue to create uncertainty in the global economic environment, with the potential to disrupt supply chains, increase commodity and energy prices, and elevate input costs for businesses. These developments may contribute to inflationary pressures, strain Pakistan's external account, and increase operating costs across industries. Although recent diplomatic developments have helped de-escalate tensions in the Middle East, providing some relief to global markets and moderated energy price pressures, the overall outlook remains subject to significant geopolitical risks. Any prolonged instability in the region could adversely affect business confidence, economic growth, and macroeconomic stability.

Creating an enabling business environment in Pakistan is essential for encouraging investment and upholding the quality standard and patient safety in our products. We will continue to work with relevant stakeholders to establish a strong regulatory framework that promotes the availability of safe and effective medicines. We also remain committed to fostering a supportive and inclusive workplace that enables our employees to deliver meaningful value to the patients and communities we serve.

Acknowledgment:
The Board of Directors would like to take this opportunity to express its deep appreciation of the commitment, resilience, courage, and dedication of its employees. We would also like to acknowledge the continued support and cooperation received from our esteemed customers, suppliers, bankers, shareholders and thank them for their confidence in our Company and products.

By order of the Board

Erum Shakir Rahim
Chief Executive Officer

Naved Masoom Ali
Director

Karachi
August 25, 2026

ڈائریکٹرز رپورٹ برائے شیئر ہولڈرز

گلیکسو اسمتھ کلائن (''کمپنی'') کے ڈائریکٹرز کے لیے یہ امر باعث مسرت ہے کہ وہ 30 جون 2026 کو ختم ہونے والی چھ ماہ کی مدت کے لیے آپ کی کمپنی کی غیر آڈٹ شدہ مالیاتی معلومات پیش کر رہے ہیں۔ یہ مالیاتی معلومات کمپنیز ایکٹ، 2017 کی دفعہ 227 کے مطابق پیش کی جا رہی ہیں۔

کاروباری ماحول اور چیلنجز

مالی سال 2026 کی پہلی ششماہی کے دوران پاکستان کی معیشت نے استحکام اور بحالی کے آثار کا مظاہرہ جاری رکھا، جبکہ مجموعی ملکی پیداوار (GDP) کی شرح نمو تقریباً 3.7 فیصد رہنے کا امکان ہے۔ اس پیش رفت کو آئی ایم ایف کے ساتھ مسلسل روابط، مالیاتی استحکام کی کوششوں اور محتاط مالیاتی و شرح مبادلہ کے انتظام سے تقویت ملی۔ مستحکم ترسیلاتِ زر کی آمد، زرمبادلہ کے مستحکم ذخائر اور پاکستانی روپے کی نسبتاً مستحکم قدر نے معاشی سرگرمیوں اور بیرونی شعبے کی مضبوطی میں معاونت کی۔ ان حوصلہ افزا پیش رفتوں کے باوجود معیشت کو اب بھی متعدد خطرات کا سامنا ہے، جن میں ساختی مسائل، عالمی توانائی کی قیمتوں میں اتار چڑھاؤ، جغرافیائی سیاسی غیر یقینی صورتحال، سپلائی چین میں رکاوٹیں، بلند افراطِ زر اور اندرونِ ملک لاگت کے دباؤ شامل ہیں، کیونکہ یہ عوامل مجموعی کاروباری ماحول پر مسلسل اثر انداز ہو رہے ہیں۔

مالی سال 27-2026 کا وفاقی بجٹ حکومت کے اس عزم کو مزید تقویت دیتا ہے کہ زیادہ ٹیکس وصولی، معیشت کی وسیع تر ڈاکومنٹیشن اور تعمیل کے اقدامات کو مضبوط بنا کر معاشی و مالیاتی استحکام حاصل کیا جائے۔ تنخواہ دار طبقے کے لیے ٹیکس میں ریلیف، کارپوریٹ اداروں کے لیے سپر ٹیکس میں کمی اور ایکٹیو فارماسیوٹیکل انگریڈینٹس (APIs) پر عائد بعض ڈیوٹیز میں ریلیف مثبت پالیسی اقدامات ہیں۔ مستقبل میں پائیدار ساختی اصلاحات اور کاروباری ماحول میں مسلسل بہتری سرمایہ کاری کے فروغ، مسابقتی صلاحیت میں اضافے اور طویل مدتی معاشی ترقی کے لیے نہایت اہم ہوں گی۔

کمپنی ،ملک میں شعبہ صحت کی ضروریات کو پورا کرنے کے لیے پُرعزم ہے اور اس بات کو یقینی بنانے کے لیے کوشاں ہے کہ مریضوں کو اعلیٰ معیار کی ادویات تک رسائی حاصل ہو، جبکہ منافع اور شیئر ہولڈرز کے منافع میں بہتری لانے کے لیے بھی اقدامات جاری ہیں۔ کمپنی ،بعض ضروری ادویات کی زیر التوا قیمتوں سے متعلق مشکلات کے معاملات اور ضروری مصنوعات سے متعلق قیمتوں کی حد کے معاملات پر متعلقہ حکام کے ساتھ مسلسل رابطے میں ہے۔ اس کے ساتھ ساتھ کمپنی پائیدار ترقی کے اقدامات، آپریشنل کارکردگی اور لاگت کو بہتر بنانے کے منصوبوں پر توجہ مرکوز کیے ہوئے ہے تاکہ طویل مدتی ترقی اور قدر میں اضافے کو یقینی بنایا جا سکے۔

آپریٹنگ نتائج کا جائزہ

30 جون 2026 کو ختم ہونے والی مدت کے لیے، کمپنی نے 31.5 ارب روپے کی سیل حاصل کی جس میںHaleon کو 0.49 ارب روپے کی فروخت شامل تھی، جبکہ گزشتہ سال کی اسی مدت میں 0.57 بلین تھی۔ ان مخصوص فروخت کو خارج کرتے ہوئے، بنیادی فروخت میں اضافہ 4.4% ہے۔ یہ اضافہ بنیادی طور پر قیمتوں میں اضافے اور ٹینڈر کاروبار کی وجہ سے ہوا ہے۔

زیر جائزہ مدت کے دوران کمپنی کا مجموعی منافع کا مارجن 37.8% فیصد رہا، جو گزشتہ مدت کے مقابلے میں 2.5% فیصد کا اضافہ ظاہر کرتا ہے۔ مجموعی منافع کی شرح میں یہ اضافہ، غیرضروری پراڈکٹس کی ڈی ریگولیشن کے ذریعے قیمتوں میں اضافے اور منافع میں بہتری و پائیداری کے لیے کیے گئے مختلف اقدامات کے باعث ہوا۔

سہ ماہی کے دوران کمپنی نے مسابقتی ترقی اور سرمایہ کاری پر زیادہ منافع حاصل کرنے کے لیے کاروبار کے اہم محرکات میں محتاط انداز میں سرمایہ کاری جاری رکھی۔

اس مدت کے دوران فی حصص آمدنی 13.17 روپے سے بڑھ کر 14.38 روپے ہو گئی۔

مستقبل کا منظر نامہ

جغرافیائی سیاسی کشیدگی اور علاقائی تنازعات سے عالمی معاشی ماحول مسلسل غیر یقینی صورتحال کا شکار ہے، جس کے باعث سپلائی چین متاثر ہونے، اشیائے ضروریہ اور توانائی کی قیمتوں میں اضافے اور کاروباری اداروں کے لیے پیداواری لاگت بڑھنے کا امکان ہے۔ یہ عوامل افراطِ زر کے دباؤ میں اضافے، پاکستان کے بیرونی کھاتے پر دباؤ اور مختلف صنعتوں میں آپریٹنگ اخراجات میں اضافے کا سبب بن سکتے ہیں۔اگرچہ حالیہ سفارتی پیش رفت نے مشرقِ وسطیٰ میں کشیدگی کو کم کرنے میں مدد دی ہے، جس سے عالمی منڈیوں کو کچھ ریلیف ملا اور توانائی کی قیمتوں پر دباؤ میں کمی آئی، تاہم مجموعی منظرنامہ اب بھی اہم جغرافیائی سیاسی خطرات سے مشروط ہے۔ خطے میں طویل عرصے تک جاری رہنے والی کسی بھی عدم استحکام کی صورتحال سےکاروباری اعتماد، معاشی ترقی اور مجموعی معاشی استحکام پر منفی اثرات مرتب ہوسکتے ہیں ۔

پاکستان میں ایسا سازگار کاروباری ماحول پیدا کرنا ضروری ہے جو سرمایہ کاری کی حوصلہ افزائی کرے اور ہماری مصنوعات کے معیار اور مریضوں کی حفاظت کے اعلیٰ معیاروں کو برقرار رکھے۔ ہم متعلقہ اسٹیک ہولڈرز کے ساتھ مل کر ایک مضبوط ریگولیٹری فریم ورک کے قیام کے لیے کام جاری رکھیں گے جو محفوظ اور مؤثر ادویات کی دستیابی کو فروغ دے۔ہم ایک معاون اور جامع کام کے ماحول کو فروغ دینے کے لیے بھی پُرعزم ہیں، جہاں ہمارے ملازمین ان مریضوں اور معاشروں کے لیے بامعنی قدر و منزلت پیدا کر سکیں جن کی ہم خدمت کرتے ہیں۔

اظہارِ تشکر

بورڈ آف ڈائریکٹرز اس موقع پر اپنے ملازمین کے عزم، ثابت قدمی، حوصلے اور لگن پر تہ دل سے ان کے شکر گزار ہے۔ہم اپنے معزز صارفین، سپلائرز، بینکرز اور شیئر ہولڈرز کی جانب سے حاصل ہونے والی مسلسل حمایت اور تعاون کو بھی قدر کی نگاہ سے دیکھتے ہیں اور کمپنی اور اس کی مصنوعات پر اعتماد کرنے پر ان سب کے بے حد شکر گزار ہیں۔

حسب الحکم بورڈ

ارم شاکر رحیم
چیف ایگزیکٹو آفیسر



نوید معصوم علی
ڈائریکٹر

کراچی
25 اگست، 2026

(Haleon Pakistan Limited (Haleon

INDEPENDENT AUDITOR'S REVIEW REPORT

TO THE MEMBERS OF GLAXOSMITHKLINE PAKISTAN LIMITED

Report on review of Interim Financial Statements

Introduction

We have reviewed the accompanying condensed interim statement of financial position of **GlaxoSmithKline Pakistan Limited** as at **June 30, 2026** and the related condensed interim statement of profit or loss and other comprehensive income, condensed interim statement of changes in equity, and condensed interim statement of cash flows, and notes to the financial statements for the half year then ended (here-in-after referred to as the "interim financial statements"). Management is responsible for the preparation and presentation of this interim financial statements in accordance with accounting and reporting standards as applicable in Pakistan for interim financial reporting. Our responsibility is to express a conclusion on these financial statements based on our review.

Scope of Review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of condensed interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial statements are not prepared, in all material respects, in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting.

Other matter

Pursuant to requirement of Section 237 (1) (b) of the Companies Act, 2017, only cumulative figures for the half year presented in the second quarter accounts are subject to a limited scope review by the statutory auditors of the company. Accordingly, the figures of the condensed interim profit or loss and other comprehensive income for the three months period ended June 30, 2026 and June 30, 2025 have not been reviewed by us.

The engagement partner on the review resulting in this independent auditor's review report is **Arif Nazeer**.

Yousuf Adil

Chartered Accountants

Place: Karachi
Date: August 27, 2026
UDIN: RR2026100998APegk5WB

CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION

AS AT JUNE 30, 2026

	Note	(Un-audited) June 30, 2026	(Audited) December 31, 2025
		Rupees in '000	
ASSETS			
Non-current assets			
Property, plant and equipment	4	**14,329,214**	14,433,368
Intangibles		**955,742**	955,742
Long-term loans to employees		**102,572**	88,201
Long-term deposits		**50,147**	50,147
		15,437,675	15,527,458
Current assets			
Stores and spares		**345,463**	293,219
Stock-in-trade	5	**15,415,665**	12,774,424
Trade receivables		**2,679,488**	2,812,639
Loans and advances		**2,590,873**	1,495,620
Trade deposits and prepayments		**286,962**	196,819
Taxation - payments less provision		**236,605**	-
Refunds due from Government	6	**1,242,846**	1,242,846
Other receivables		**5,919,754**	7,748,331
Cash and bank balances		**8,425,602**	8,592,146
		37,143,258	35,156,044
Total assets		**52,580,933**	50,683,502
EQUITY AND LIABILITIES			
SHARE CAPITAL AND RESERVES			
Share capital		**3,184,672**	3,184,672
Reserves		**31,248,998**	30,489,961
Total equity		**34,433,670**	33,674,633
LIABILITIES			
Non-current liabilities			
Staff retirement benefits		**452,939**	612,437
Deferred taxation		**1,082,353**	927,427
Lease liabilities		**324,996**	335,139
		1,860,288	1,875,003
Current liabilities			
Trade and other payables	7	**15,836,287**	13,736,274
Taxation - provision less payments		**-**	989,290
Provisions	8	**229,111**	207,937
Current portion of lease liabilities		**28,400**	32,974
Unclaimed dividend		**193,177**	167,391
		16,286,975	15,133,866
Total liabilities		**18,147,263**	17,008,869
Total equity and liabilities		**52,580,933**	50,683,502
Contingencies and commitments	9		

The annexed notes from 1 to 21 form an integral part of these condensed interim financial statements.

Director   Acting Chief Financial Officer   Director

CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UN-AUDITED)

FOR THE HALF YEAR ENDED JUNE 30, 2026

	Note	Quarter ended		Half year ended	
		June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
		---------------- Rupees in '000 ----------------			
Revenue from contracts with customers - net	10	**14,490,967**	14,720,667	**31,519,292**	30,300,807
Cost of sales		**(8,952,110)**	(9,344,065)	**(19,597,073)**	(19,598,316)
Gross profit		**5,538,857**	5,376,602	**11,922,219**	10,702,491
Selling, marketing and distribution expenses	11	**(1,443,035)**	(1,521,892)	**(2,738,931)**	(2,586,108)
Administrative expenses		**(675,835)**	(479,878)	**(1,258,385)**	(1,018,030)
Other operating expenses		**(301,363)**	(304,901)	**(676,835)**	(613,537)
Other income	12	**531,262**	525,529	**713,172**	744,793
Operating profit		**3,649,886**	3,595,460	**7,961,240**	7,229,609
Financial charges		**(6,176)**	(100,317)	**(29,525)**	(214,416)
Profit before levies and income tax		**3,643,710**	3,495,143	**7,931,715**	7,015,193
Levies - Minimum tax		**-**	-	**-**	-
Profit before income tax		**3,643,710**	3,495,143	**7,931,715**	7,015,193
Income tax - net	13	**(1,673,771)**	(1,426,332)	**(3,351,071)**	(2,819,836)
Profit after taxation		**1,969,939**	2,068,811	**4,580,644**	4,195,357
Other comprehensive income		**-**	-	**-**	-
Total comprehensive income		**1,969,939**	2,068,811	**4,580,644**	4,195,357
Earnings per share - Rupees	14	**6.19**	6.50	**14.38**	13.17

The annexed notes from 1 to 21 form an integral part of these condensed interim financial statements.

Director

Acting Chief Financial Officer

Director

CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY (UN-AUDITED)

FOR THE HALF YEAR ENDED JUNE 30, 2026

		Capital reserves	Revenue reserves			
	Share capital	Reserve arising on schemes of arrangements	General reserve	Unappropriated profit	Total Reserves	Total
	----------------------------- Rupees in '000 -----------------------------					
Balance as at January 1, 2025	3,184,672	1,126,923	3,999,970	19,964,976	25,091,869	28,276,541
Transactions with owner recorded directly in equity - distribution						
Final dividend for the year ended December 31, 2024 @ Rs. 10 per share	-	-	-	(3,184,673)	(3,184,673)	(3,184,673)
Total comprehensive income for the half year ended June 30, 2025	-	-	-	4,195,357	4,195,357	4,195,357
Balance as at June 30, 2025	3,184,672	1,126,923	3,999,970	20,975,660	26,102,553	29,287,225
Balance as at January 1, 2026	**3,184,672**	**1,126,923**	**3,999,970**	**25,363,068**	**30,489,961**	**33,674,633**
Transactions with owner recorded directly in equity - distribution						
Final dividend for the year ended December 31, 2025 @ Rs. 12 per share	**-**	**-**	**-**	**(3,821,607)**	**(3,821,607)**	**(3,821,607)**
Total comprehensive income for the half year ended June 30, 2026	**-**	**-**	**-**	**4,580,644**	**4,580,644**	**4,580,644**
Balance as at June 30, 2026	**3,184,672**	**1,126,923**	**3,999,970**	**26,122,105**	**31,248,998**	**34,433,670**

The annexed notes from 1 to 21 form an integral part of these condensed interim financial statements.

Director | Acting Chief Financial Officer | Director

CONDENSED INTERIM STATEMENT OF CASH FLOWS (UN-AUDITED)

FOR THE HALF YEAR ENDED JUNE 30, 2026

	Note	Half year ended June 30, 2026	Half year ended June 30, 2025
		------------ Rupees in '000 ------------	
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	15	**8,664,487**	6,987,452
Contribution to staff retirement benefit fund		**(348,452)**	(79,942)
Income taxes paid		**(4,422,040)**	(3,145,530)
(Decrease) / increase in long-term loans to employees		**(14,371)**	1,048
Net cash generated from operating activities		**3,879,624**	3,763,028
CASH FLOWS FROM INVESTING ACTIVITIES			
Fixed capital expenditures		**(737,530)**	(934,713)
Proceeds from disposal of operating assets		**165,493**	166,128
Return received on bank balances and investments		**359,999**	204,639
Net cash used in investing activities		**(212,038)**	(563,946)
CASH FLOWS FROM FINANCING ACTIVITIES			
Lease rentals paid		**(38,309)**	(27,848)
Dividend paid		**(3,795,821)**	(3,159,035)
Net cash used in financing activities		**(3,834,130)**	(3,186,883)
Net (decrease) / increase in cash and cash equivalents during the period		**(166,544)**	12,199
Cash and cash equivalents at the beginning of the period		**8,592,146**	6,513,447
Cash and cash equivalents at the end of the period	16	**8,425,602**	6,525,646

The annexed notes from 1 to 21 form an integral part of these condensed interim financial statements.

Director

Acting Chief Financial Officer

Director

CONDENSED INTERIM NOTES TO THE FINANCIAL STATEMENTS (UN-AUDITED)

FOR THE HALF YEAR ENDED JUNE 30, 2026

1. THE COMPANY AND ITS OPERATIONS

GlaxoSmithKline Pakistan Limited (the Company) is incorporated in Pakistan as a limited liability company and is listed on the Pakistan Stock Exchange. The registered office of the Company is situated at 35 - Dockyard Road, West Wharf, Karachi, Sindh. It is engaged in manufacturing and marketing of research based ethical specialties and pharmaceutical products.

The Company is a subsidiary of GSK International Holding and Finance B.V., incorporated in Netherlands, whereas its ultimate parent company is GSK plc, UK.

1.1 Due to the pending transfer of marketing authorisations and permissions for certain Over the Counter (OTC) products of Haleon Pakistan Limited with Drug Regulatory Authority of Pakistan (DRAP), the Company, for and on behalf of Haleon Pakistan Limited was engaged in the procurement, manufacturing and managing the related inventory and receivable balances pertaining to such products against a service fee charged by the Company. The marketing authorisation and permissions for certain OTC products were transferred to Haleon Pakistan Limited and therefore, Haleon Pakistan Limited is now involved in procurement, manufacturing and managing of such inventory items since approval date.

2. BASIS OF PREPARATION

These condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

- International Accounting Standard 34: 'Interim Financial Reporting' (IAS 34), issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017 (the Act); and
- Provisions of and directives issued under the Act.

Where the provisions of and directives issued under the Companies Act, 2017, differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017, have been followed.

2.1 The disclosures made in these condensed interim financial statements have, however, been limited based on the requirements of IAS 34. These condensed interim financial statements do not include all the information and disclosures required in a full set of financial statements and should be read in conjunction with the annual audited financial statements of the Company for the year ended December 31, 2025.

2.2 These condensed interim financial statements are unaudited. However, a limited scope review of these condensed interim financial statements has been performed by the external auditors of the Company in accordance with the requirements of Rule Book of Pakistan Stock Exchange Limited and they have issued their review report thereon. These condensed interim financial statements are submitted to the shareholders as required by section 237 of the Companies Act, 2017.

2.3 The comparative condensed interim statement of financial position presented has been extracted from annual audited financial statements for the year ended December 31, 2025, whereas comparative condensed interim statement of profit or loss and other comprehensive income, condensed interim statement of cash flows and condensed interim statement of changes in equity are extracted from the un-audited condensed interim financial statements for the half year ended June 30, 2025.

2.4 Application of new standards, interpretations and amendments to the published approved accounting and reporting standards that are effective during the period

The following amendments are effective for the year ending December 31, 2026. These amendments are either not relevant to the Company's operations or are not expected to have significant impact on the Company's condensed interim financial statements other than certain additional disclosures:

- Amendments to IFRS 9 and IFRS 7 regarding the classification and measurement of financial instruments	January 01, 2026
- Annual Improvements to IFRS Accounting Standards (related to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7)	January 01, 2026
- Amendments to IFRS 9 and IFRS 7 regarding power purchase arrangements	January 01, 2026

3. MATERIAL ACCOUNTING POLICIES, RISK MANAGEMENT POLICIES, ESTIMATES AND JUDGEMENTS

3.1 Material accounting policies

The material accounting policies applied in the preparation of these condensed financial statements are the same as those applied in the preparation of the audited financial statements of the Company for the year ended December 31, 2025.

3.2 Financial risk management

The Company's financial risk management objective and policies are consistent with those disclosed in the annual audited financial statements of the Company for the year ended December 31, 2025.

3.3 Estimates and judgments

Estimates and judgments made by management in the preparation of these condensed interim financial statements are same as those applied in the preparation of the annual audited financial statements of the Company for the year ended December 31, 2025.

4. PROPERTY, PLANT AND EQUIPMENT

	Note	(Un-audited) June 30, 2026	(Audited) December 31, 2025
		---------- Rupees in '000 ----------	
Operating assets	4.1	**10,847,801**	10,535,572
Capital work-in-progress		**2,939,405**	3,333,230
Right-of-use assets - land and buildings		**282,036**	310,444
Major spare parts		**259,972**	254,122
		14,329,214	14,433,368

4.1 Details of additions to and disposals of operating assets are as follows:

	(Un-audited) Additions (at cost)		(Un-audited) Disposals (at net book value)	
	Half year ended		Half year ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
	------------------------------- Rupees '000 -------------------------------			
Buildings on leasehold land	**77,958**	275,342	**-**	-
Plant and machinery	**846,673**	256,867	**-**	1,337
Furniture and fixtures	**7,687**	84,783	**-**	-
Vehicles	**113,936**	513,043	**84,375**	123,953
Office equipments	**73,266**	323,623	**430**	379
	1,119,520	1,453,658	**84,805**	125,669

5. STOCK-IN-TRADE	(Un-audited) June 30, 2026	(Audited) December 31, 2025
	------------ Rupees '000	------------
Raw and packing material	**7,393,625**	6,871,844
Work-in-process	**432,260**	357,922
Finished goods	**8,430,920**	6,732,702
	16,256,805	13,962,468
Less: Provision for slow moving, obsolete and damaged items	**(841,140)**	(1,188,044)
	15,415,665	12,774,424

5.1 Finished goods includes items costing Rs. 1.39 billion (December 31, 2025: Rs. 2.6 billion) valued at net realizable value of Rs. 1.11 billion (December 31, 2025: Rs. 2.1 billion). Raw and packing materials have been lowered by Rs. 110.01 million (December 31, 2025: Rs. 88.96 million) and WIP has been lowered by Rs. 29.35 million (December 31, 2025: Rs. 37.75 million) respectively to recognize them at net realizable value.

6. REFUNDS DUE FROM GOVERNMENT

Prior to enactment of Finance (Supplementary) Act, 2022 (The Act) issued on January 15, 2022, the pharmaceutical sector was exempt from levy of sales tax. The Act converted the aforesaid exemption regime into a zero-rating regime for import and local supplies for finished items of pharmaceutical sector, however, sales tax was imposed on purchase / import of Active Pharmaceutical Ingredients (API). As a result, the pharmaceutical sector was allowed to claim sales tax refund on all purchases including APIs and provincial sales tax on services. As of June 2026, Sales tax refund of Rs. 1.17 billion was outstanding. In the year 2025, the Company was issued Refund Payment Orders (RPOs) amounting to Rs. 0.289 billion and Rs. 0.209 billion respectively. These amounts are yet to be received.

Through Finance Act, 2022, effective from July 1, 2022, a special tax regime for pharmaceutical sector was introduced whereby manufacture or import of substances registered as drugs under the Drugs Act, 1976 shall be subject to 1% sales tax with the condition that such tax shall be final discharge of tax in the supply chain and no input tax shall be allowed to the importer and manufacturer of such goods. Therefore, the input tax is becoming part of cost.

7. TRADE AND OTHER PAYABLES	(Un-audited) June 30, 2026	(Audited) December 31, 2025
	------------ Rupees '000	------------
Creditors and bills payable	**4,338,855**	3,099,608
Accrued liabilities	**5,092,477**	5,770,253
Others liabilities	**3,966,342**	3,033,501
Contract liabilities	**2,438,613**	1,832,912
	15,836,287	13,736,274

8. PROVISIONS

Provisions include restructuring costs and government levies of Rs. 31.81 million and Rs. 197.3 million (December 31, 2025: Rs 31.81 million and Rs. 176.13 million) respectively.

9. CONTINGENCIES AND COMMITMENTS

9.1 The changes in the status of contingencies as reported in the audited financial statements for the year ended December 31, 2025 are followings;

(a) Income Tax

(i) During the year, the Company received a show cause notice from the Federal Board of Revenue (FBR) proposing recovery of default surcharge of Rs. 197.4 million under Section 205 of the Income Tax Ordinance, 2001 for tax year 2022. The notice alleged that Super Tax payable under Section 4C, amounting to Rs. 412.24 million, had not been discharged within the prescribed time. Subsequently, the tax authorities passed an order under Section 4C raising a tax demand of Rs. 164.8 million. The Company has filed an appeal against the said order before the Commissioner Inland Revenue Appeals (CIRA), which is currently pending adjudication.

(b) Sales Tax

(i) During the year, the Company received a show cause notice from FBR for the period from February 2022 to June 2022. Through the notice the it was asserted that the company has claimed inadmissible input tax of Rs. 92 million and has claimed input tax of Rs. 627 million without providing any documentary evidences. The company has responded to the show cause notice accordingly but the officer passed order and raised sales tax demand of Rs. 630.98 million against which the company has filed an appeal before CIRA which is pending for adjudication.

The management is confident that the ultimate decision in the above case will be in favour of the Company, hence, no provision has been recognised in respect of the aforementioned matter.

9.2 Commitments for capital expenditure outstanding as at June 30, 2026, amounted to Rs. 500.01 million (December 31, 2025: Rs. 699.13 million).

9.3 The facilities for opening letters of credit and guarantees as at June 30, 2026, amounted to Rs. 7.18 billion (December 31, 2025: Rs. 7.18 billion) of which the amount remaining unutilised at period end was Rs. 4.02 billion (December 31, 2025: Rs. 5.3 billion).

10. REVENUE FROM CONTRACTS WITH CUSTOMERS - NET

10.1 This include sales of Over the Counter Products (OTC) amounting to Rs. 0.49 billion (June 30, 2025: Rs. 0.57 billion) to Haleon Pakistan Limited being manufactured by the Company due to pending transfer of marketing authorisations by DRAP - refer note 1.1.

11. SELLING, MARKETING AND DISTRIBUTION EXPENSES

This includes advertising and sales promotion expenses of Rs. 519.87 million (June 30, 2025: Rs. 485.07 million).

12. OTHER INCOME

		(Un-audited)			
		Quarter ended		Half year ended	
	Note	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
		------------ Rupees '000 ------------			
Income from financial assets					
Income on savings and deposit accounts		**355,670**	199,833	**359,999**	204,639
Income from non-financial assets					
Gain on disposal of operating assets		**63,072**	31,018	**80,688**	40,459
Others					
Scrap sales		**27,675**	27,179	**60,533**	47,338
Promotional allowance	12.1	**62,361**	241,880	**163,118**	395,926
Service fee		**2,100**	3,993	**4,200**	7,986
Others		**20,384**	21,626	**44,634**	48,445
		531,262	525,529	**713,172**	744,793

12.1 This represents allowance from GSK Group against various promotional activities for brand building and sustainable returns on investments.

13. TAXATION - NET

The Government of Pakistan through Finance Act, 2022 introduced section 4C in the Income Tax Ordinance, 2001 through which super tax was levied on high earning persons. The Company along with other entities (petitioners), in connected petitions, challenged the vires of section 4C before Sindh High Court (SHC). The SHC vide order dated December 22, 2022, declared that section 4C shall not be applicable for TY 2022.

The aforesaid judgment was challenged by the department before the Supreme Court of Pakistan (SC). The SC vide order dated February 16, 2023, gave directions to deposit super tax @ 4% and to furnish Bank Guarantee for the remaining 6% as an interim relief till final judgment is passed. The Company complied with aforesaid directions.

The Government of Pakistan through Finance Act, 2023 enhanced the rates of super tax under section 4C of the Income Tax Ordinance, 2001 for tax year 2023 and onwards on high earning persons. The tax is applicable at progressive rates on all persons (including company) earning more than Rs. 150 million. Accordingly, the Company booked a prior year charge of Rs. 302.44 million on account of super tax in financial year 2023.

In December 2023, the Company along with other petitioners challenged the amendment in super tax rates for tax year 2023 in the Islamabad High Court (IHC). The Hon'ble IHC granted stay against increase in super tax rates from 4% to 10% and decided in favor of the petitioners on the issue of maintainability raised by the tax department. The tax department has challenged the orders of IHC before the Supreme Court of Pakistan (SC), which vide order dated 27 February 2024 remanded back the case to IHC with directions to pass detailed order on the issue of maintainability of jurisdiction and then decide on interim relief. Following the order of SC, the Hon'ble IHC has passed interim order dated 4 March 2024 and directed the Chief Commissioner Karachi for not taking any coercive measures till the final decision of main appeal pending before IHC.

Pursuant to the order of SC, the IHC has passed an order on March 15, 2024, whereby the petitions of the taxpayers were held maintainable. The increase in super tax rates from 4% to 10% has been declared null and void by the court, citing its earlier judgment and deeming the retrospective increase in tax, as invalid. The tax department has filed an Intra-Court Appeal (ICA), which was pending for hearing at SC.

In January 2026, the Federal Constitutional Court disposed off the petitions and upheld the validity of Section 4C, thereby confirming the levy of super tax. Pursuant to the said order, the Company has paid the outstanding super tax liability, including super tax at 6% in respect of financial year 2021 and 2022 accordingly.

14. EARNINGS PER SHARE - BASIC AND DILUTED

	(Un-audited)			
	Quarter ended		Half year ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
	Rupees '000			
Profit after taxation	**1,969,939**	2,068,811	**4,580,644**	4,195,357
	Number of shares			
Weighted average number of outstanding shares	**318,467,278**	318,467,278	**318,467,278**	318,467,278
	Rupees			
Earnings per share - basic and diluted	**6.19**	6.50	**14.38**	13.17

14.1 A diluted earnings per share has not been presented as the Company did not have any convertible instruments in issue which would have any effect on the earnings per share if the option to convert is exercised.

15. CASH GENERATED FROM OPERATIONS

	(Un-audited) Half year ended June 30, 2026	(Un-audited) Half year ended June 30, 2025
	------------ Rupees '000	------------
Profit before taxation	**7,931,715**	7,015,193
Add / (less): Adjustments for non-cash charges and other items		
Depreciation and impairment	**756,879**	661,127
Provision for slow moving, obsolete and damaged stock-in-trade net of stock written-off	**165,302**	707,086
Gain on disposal of operating assets	**(80,688)**	(40,459)
Interest income	**(359,999)**	(204,639)
Interest on lease liabilities	**23,592**	20,375
Provision for staff retirement benefits	**188,954**	176,561
Unrealised exchange (gain) / loss	**(56,984)**	93,470
Profit before working capital changes	**8,568,771**	8,428,714
Effect on cash flow due to working capital changes		
(Increase) / decrease in current assets		
Stores and spares	**(52,244)**	(50,758)
Stock-in-trade	**(2,806,543)**	(3,714,322)
Trade receivables	**133,151**	223,141
Loans and advances	**(1,095,253)**	(579,042)
Trade deposits and prepayments	**(90,143)**	(132,177)
Other receivables	**1,828,577**	846,945
	(2,082,455)	(3,406,213)
Increase / (decrease) in current liabilities		
Trade and other payables	**2,156,997**	1,912,714
Provisions	**21,174**	52,237
	2,178,171	1,964,951
	8,664,487	6,987,452

16. CASH AND CASH EQUIVALENTS

	(Un-audited) June 30, 2026	(Audited) December 31, 2025	(Un-audited) June 30, 2025
	--------------------	Rupees '000	--------------------
Cash and bank balances	**8,425,602**	8,592,146	6,525,646

17. TRANSACTIONS WITH RELATED PARTIES

The related parties include holding company, associated companies, directors and key management personnel of the Company and companies where directors also hold directorships. The transactions with related parties are carried out in the normal course of business at contracted rates duly approved by Board of Directors. Details of transactions with related parties and balances with them at period end, other than those which have been disclosed elsewhere in these condensed interim financial statements, are as follows:

17.1 Transactions carried out during the period are as follows:

Relationship	Nature of transactions	(Un-audited) Half year ended June 30, 2026	(Un-audited) Half year ended June 30, 2025
		------------ Rupees '000	------------
Associated companies / undertakings	a. Royalty expense charged	**323,637**	324,101
	b. Purchase of goods	**3,633,346**	1,917,337
	c. Sale of goods	**-**	12,299
	d. Recovery of expenses	**680,917**	733,814
	e. Promotional allowance	**163,118**	395,926
Staff retirement funds:	a. Payments to retirement benefit plans	**480,716**	187,929
Key management personnel:	a. Salaries and other employee benefits	**417,364**	337,909
	b. Post employment benefits	**24,682**	24,051
	c. Sale of assets - sales proceeds	**3,126**	21,007

17.2 Outstanding balances as at period / year end are as follows:

	(Un-audited) June 30, 2026	(Audited) June 30, 2025
	------------ Rupees '000	------------
Associated companies:		
Other receivable	**5,573,879**	8,115,304
Trade and other payables	**2,262,209**	2,606,649
Provision for staff retirement benefits	**452,939**	732,983

18. DISCLOSURE REQUIREMENTS FOR COMPANIES NOT ENGAGED IN SHARIAH NON-PERMISSIBLE BUSINESS ACTIVITIES

Description	(Un-audited) June 30, 2026	(Audited) December 31, 2025
	------------ Rupees '000	------------
Statement of Financial Position:		
Bank balances - Shariah compliant	**2,849**	2,820

	(Un-audited)	(Un-audited)
	Half year ended	
	June 30, 2026	June 30, 2025
	------------ Rupees ‘000 ------------	
Statement of Profit or Loss and Other Comprehensive Income:		
Revenue earned from shariah compliant business	**31,519,292**	30,300,807
Profit on bank deposits - Islamic	**36**	61
Break-up of other income excluding profits on shariah compliant bank deposits		
Shariah compliant Income		
Gain on disposal of operating assets	**80,688**	40,459
Scrap sales	**60,533**	47,338
Promotional allowance	**163,118**	395,926
Service fee	**4,200**	7,986
Others	**44,634**	48,445
Shariah non-compliant income		
Income on savings account - conventional	**359,963**	204,578

Relationship with shariah compliant banks

Name	Relationship
Meezan Bank Limited	Bank Balance

19. FAIR VALUE MEASUREMENTS

IFRS 13 “Fair Value Measurement” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. It requires categorization of fair value measurements into different levels of fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices).

Level 3: Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs).

As at June 30, 2026, the Company does not have any financial instruments carried at fair values which are measured using method falling under above categories, and carrying value of financial assets and liabilities approximate their fair value at the reporting date.

20. SUBSEQUENT EVENTS

The Board of Directors in its meeting held on August 25, 2026 have declared and approved an interim cash dividend for the period ended of Rs. 7 per share (June 30, 2025: Rs. 5 per share) amounting to Rs. 2,229 million (June 30, 2025: Rs. 1,592 million).

21. DATE OF AUTHORISATION FOR ISSUE

These condensed interim financial statements were approved and authorised for issue by the Board of Directors of the Company on August 25, 2026.

Director	Acting Chief Financial Officer	Director

GlaxoSmithKline Pakistan Limited
35 - Dockyard Road, West Wharf, Karachi - 74000
GlaxoSmithKline Pakistan Limited is a member of GSK group of Companies.

© GlaxoSmithKline Pakistan Limited

Printed by YAQEEN.biz